CYCLE

📅 Upcoming

🕒 Recent(90d)

News

• TScan axes 75% of workforce, prioritizes solid tumor program
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 21h ago
• Biopharma needs more data scientists. Who's getting hired?
  With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the qualifications, technical skills and mindset needed to land these covete…
  biospace · 2d ago
• Follow the money: How funding announcements can help identify jobs before they’re posted
  Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the funding…
  biospace · 2d ago
• UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease
  The biologics license application follows months of public speculation—and regulatory reversals—for uniQure’s AMT-130. If accepted by the FDA for priority review, approval could come in the second…
  biospace · 2d ago
• Opinion: The next DSM should address the algorithm’s role in eating disorders
  The new DSM, expected in 2030, should address the digital environments of eating disorders patients, experts write.
  stat · 3d ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 3d ago
• Opinion: I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field
  “The whole of my field has been flattened into a single lazy question: Did the health care system fail her?” writes Jennifer Okwerekwu.
  stat · 3d ago
• STAT+: Will House delay Trump plan to politicize NIH grants?
  The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.
  stat · 3d ago
• Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
  The approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…
  biospace · 5d ago
• Hospitals are plotting a long-shot push to roll back $1 trillion in Medicaid cuts
  Inside health systems' efforts to mitigate massive funding cuts.
  stat · 9d ago